SCHEMBL6497797

SCHEMBL6497797

COc1ccccc1-c1ccc(C(=O)NC2CC3CC2CN3)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.51
KDM4E B2RXH2 5/20 0.51
HPGD P15428 5/20 0.51
HSD17B10 Q99714 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
SLC9A1 P19634 1/20 0.46
MAPT P10636 9/20 0.45
LMNA P02545 5/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TSHR P16473 1/20 0.45
ATM Q13315 1/20 0.45
NPC1 O15118 4/20 0.44
CHRNA7 P36544 1/20 0.43
HTR3A P46098 1/20 0.43
ABCB1 P08183 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488977 0.87 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDSLC9A1MAPT
SCHEMBL6498429 0.86 RAB9A (0.40) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6498308 0.85 RAB9A (0.53) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6497808 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6486675 0.85 SLC9A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6499361 0.84 HDAC1 (0.53) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6488018 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6487086 0.83 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL7232158 0.82 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL6489856 0.82 ERCC5 (0.45) ALDH1A1KDM4EHPGDSLC9A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
EP-1442041-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-08-04 EP disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
WO-2003040147-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ PHARMACIA & UPJOHN COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885KDM4E 2799/4885HPGD 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.